Nivolumab in nonsquamous non-small-cell lung can- cer. N Engl J Med. 2016;374(5):493-494.Nivolumab in nonsquamous non-small-cell lung cancer. Borghaei H,Brahmer J. The New England Journal of Medicine . 2016Borghaei H, Brahmer J. Nivolumab in Nonsquamous Non-Small-Cell Lung...
Introduction: Nonsquamous non-small-cell lung cancer (NSCLC) is divided in oncogene-addicted subgroups, highly expressed programmed death ligand-1 (PD-L1鈮 50%) subgroup, and 'negative' subgroup. The latter represents the most common group comprising about 50% of all new diagnoses of non...
First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer :analy- sis of the Italian patients enrolled in the SAiL study[ J ]. Clin Drug In- vestig,2012,32( 11 ) :755-760.Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. ...
Pemetrexed in Nonsquamous Non–Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis 来自 NCBI 喜欢 0 阅读量: 10 作者:B Gyawali,V Prasad 摘要: Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study...
Non-small cell lung cancer (NSCLC) represents the most common cause of cancer mortality worldwide and counts for the greatest number of deaths from lung cancer in both men and women over age 60. Pemetrexed is a multi-targeted anti-metabolite and has shown comparable activity for Caucasian patie...
Lung Diseases Department, San Camillo-Forlanini High Specialization Hospitals, Rome, Italy; 2Sperimental Medicine Department, Rome, Italy Abstract: Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination...
Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients Annals of OncologyF. GrossiL. CrinòA. DelmonteD. TurciG. Lo RussoF. De MarinisH.J. Soto ParraD. GalettaF. CappuzzoF. SperandiM. TiseoG. PuppoF. RoilaM.R. MigliorinoG...
Lung Cancer: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Review Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer This article was published in the following Dove Press journal: Lung Cancer:Targets ...
non-squamous non-small cell lung cancerPD-1/PD-L1predictiveimmunotherapyBackground: Genetic variations in non-small cell lung cancer (NSCLC) have been shown potential impact on immune microenvironment, and associated with response odoi:10.2139/ssrn.3384916Dong, Zhong-yi...
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL PURPOSE: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, improves survival when combined with carboplatin/paclitaxel for...